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Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic bladder condition characterized by
bladder pain, frequency and nocturia. There is no deﬁnite treatment providing a long-term cure for IC/
PBS. Recent studies have demonstrated that intravesical botulinum toxin A (BoNT-A) has promising
effects on IC/PBS. Repeated BoNT-A injections might provide long-term symptom relief and decrease
glomerulations after cystoscopic hydrodistention. Our previous studies demonstrated bladder tissue
nerve growth factor is elevated in IC/PBS bladders and decreased in responders to BoNT-A injection
associated with decreased visual analog pain scores. Another study revealed that increased urothelial cell
apoptosis, decreased cell proliferation, increased mast cell activation, and impaired expression of junc-
tion protein E-cadherin were signiﬁcant in IC/PBS bladders. Further study of apoptotic markers and
inﬂammatory protein expression also revealed that apoptotic signaling molecules, including Bad, Bax,
and caspase 3, were increased in the bladder tissues of patients with IC/PBS. The apoptosis and growth
arrest of bladder tissues of IC/PBS patients could be due to upregulation of inﬂammatory signals,
including p38 mitogen-activated protein kinase and tumor necrosis factor alpha. We reviewed the
possible pathologic mechanisms of the therapeutic effects of intravesical BoNT-A injection and presented
the results of our pilot studies of BoNT-A injections for IC/PBS.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) is
a chronic bladder condition characterized by bladder pain,
frequency, and nocturia. There is no deﬁnite treatment providing
a long-term cure of IC/PBS. Recent studies have demonstrated that
intravesical botulinum toxin A (BoNT-A) has promising effects on
IC/PBS. Repeated BoNT-A injections might provide long-term
symptom relief and decrease glomerulations after cystoscopic
hydrodistention. We reviewed the possible pathologic mechanisms
of the therapeutic effects of intravesical BoNT-A injection and
presented the results of our pilot studies on improvement of
bladder inﬂammation and urothelial cell growth in bladder tissue
specimens after BoNT-A injections.Buddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
ddhist Compassion Relief Tzu Chi2. Pathogenesis of IC/PBS
The cause of IC/PBS may be the result of long-standing inﬂam-
mation of the bladder; however, the actual pathophysiology
remains unclear. The most common clinical presentations of IC/PBS
are bladder and pelvic pain, glomerulations under cystoscopic
hydrodistention, denudation, or thinning of the bladder epithe-
lium, suggesting bladder inﬂammation and urothelial dysfunction
[1,2]. However, the molecular mechanisms are still not well eluci-
dated. Yamada and colleauges [3] demonstrated an apoptotic
process in the microvascular endothelial cells of bladders with IC/
PBS. A recent study further revealed that urothelial homeostasis in
IC/PBS bladders was signiﬁcantly impaired, and the abnormal
urothelial function was associated with chronic inﬂammation of
the bladder [4].
The chronic pain in IC/PBS may occur because of central nervous
system sensitization and persisting abnormalities in the urinary
bladder that activate the afferent sensory system [5]. Recent ﬁnd-
ings have proposed several pathophysiologic mechanisms
including epithelial dysfunction, activation of mast cells, neuro-
genic inﬂammation, autoimmunity and occult infection. EvidenceFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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two subtypes, the ulcer type (classic) and nonulcer type, may
represent different disease entities [6]. The diagnosis of IC/PBS can
only be made by clinical symptoms and cystoscopic hydro-
distention under anesthesia and exclusion of other bladder disor-
ders [7].
Recent studies have shown that the lamina propria of the
bladder plays an important role in transmitting bladder sensation
and the response of the bladder to chemical stimuli and inﬂam-
mation [8e10]. In the urinary tract, nerve growth factor (NGF) is
produced by bladder smooth muscle and urothelium [11]. Previous
studies have found that NGF is involved in the ongoing regulation of
neural function in conditions such as spinal cord injury and
denervation, as well as inﬂammation, and produces pain [5,11,12].
Increased levels of NGF have also been reported in the bladder
tissue and urine of patients with painful inﬂammatory conditions
of the lower urinary tract, such as sensory urgency and IC/PBS
[13,14].
Bladder inﬂammation in chemically induced cystitis or intra-
vesical NGF instillation leads to acute afferent nerve activity and
long-term plasticity that lowers the threshold for nociceptive and
mechanoreceptive afferent ﬁbers [15e17]. Chronic sensitization
of afferent ﬁbers might involve both peripheral and central
mechanisms. A rise in bladder NGF in the muscle or urothelium
initiates signals had been found to transport along the afferent
nerves of the bladder to the dorsal root ganglion (DRG) or the
spinal cord, which may further trigger bladder overactivity
during subsequent stimulation [18,19]. Intravesical injection of
BoNT-A has been found to reduce bladder pain in IC/PBS patients
refractory to conventional treatment [20]. The NGF levels in the
bladder tissue have been found signiﬁcantly increased in patients
with IC/BPS and decreased to the normal range after BoNT-A
treatment [21].
Histologic investigations of the bladder urothelium and sub-
urothelium have found that signs of chronic inﬂammation were
present in 60% of baseline biopsies of patients with overactive
bladder (OAB) [22]. The expression of inﬂammatory markers such
as mast cells in IC/PBS is similar to that in OAB [23]. OAB could be
a subtype of neurogenic inﬂammation characterized by a series of
vascular and nonvascular inﬂammatory responses triggered by
the activation of primary sensory neurons and the subsequent
release of inﬂammatory neuropeptides, including substance P
and calcitonin gene-related peptide [24]. The inﬂammatory
response-induced overexpression of transient receptor potential
vanilloid receptor subfamily type 1 in the suburothelium as well
as c-fos protein in the DRG have been demonstrated in rat models
of OAB and in human bladder biopsies [8,10,18]. Urinary inﬂam-
matory biomarkers such as NGF were also noted to elevate in
patients with OAB as well as IC/BPS [25]. A recent investigation of
urinary chemokines in OAB patients also showed increased
monocyte chemotactic protein-1 (MCP-1) and some proin-
ﬂammatory cytokines. A greater than tenfold elevation in the
levels of MCP-1 and the soluble fraction of the CD40 ligand was
obtained from the urine of OAB patients relative to controls. At
least ﬁvefold elevations were detected in the levels of macro-
phage inﬂammatory protein, interleukin (IL)-12p70/p40, IL-5,
epidermal growth factor (EGF), and growth-related oncogene-
a compared with controls. A signiﬁcant threefold elevation was
also noted in the urine levels of sIL-2Ra, and IL-10 in patients
with OAB [26].
IC/BPS involves an aberrant differentiation program in the
bladder urothelium that leads to altered synthesis of several
proteoglycans, cell adhesion and tight junction proteins, and
bacterial defense molecules such as GP51. These ﬁndings have led
to the rationale for selecting some urinary markers to detect thepresence of IC/BPS [27]. The potential biomarkers for detection of
IC/PBS in recent studies are antiproliferative factor (APF), EGF,
heparin-binding epidermal growth factor, glycosaminoglycans, and
bladder nitric oxide [28].3. Chronic inﬂammation and apoptosis in IC/PBS
Chronic inﬂammation is a medical condition characterized by
persistent inﬂammatory processes in the tissue. A number of
diseases can be included in this category, such as atherosclerosis,
cancer, heart valve dysfunction, obesity, diabetes, congestive heart
failure, digestive system diseases, Alzheimer disease, and bladder
disorders such as IC/PBS. Excessive levels of one or more of the
inﬂammatory cytokines, e.g., tumor necrosis factor alpha (TNFa), IL-
6, or IL-8, are usually found in chronic inﬂammatory diseases [29].
TNFa also promotes apoptosis through binding to TNF-receptor 1,
resulting in many effects ranging from inﬂammation to apoptosis
[30]. The primary role of TNFa is in the regulation of immune cells,
and it can also induce apoptotic cell death through activation of the
transcription factor nuclear factor kappa B and c-Jun N-terminal
kinase [31].
Several previous studies have indicated that p38 mitogen-
activated protein kinase (MAPK) activation is implicated in
inﬂammation, tissue ﬁbrosis and mediating apoptosis in different
cell types in various species [32,33]. Apoptosis is a major form of
cell death, characterized initially by a series of stereotypic
morphological changes. It is well known that the p38 MAPK
pathway participates in the apoptotic process through the regula-
tion of P53 activation [34,35]. Although this signaling pathway is
important in the coordination of cellular responses tomany stimuli,
the effect of the p38 MAPK pathway in IC/PBS has not been well
deﬁned [36]. P38 MAPK was recently found to be an important
mediator of the anti-proliferative effects of APF in bladder uro-
thelial cells [37]. Our recent study showed that apoptotic signaling
molecules, including Bad, Bax, and cleaved caspase-3, were
increased in the bladder tissues of IC/PBS patients [38]. The results
suggest that apoptosis in IC/PBS bladders might be due to upre-
gulation of inﬂammatory signals. Moreover, the onset of inﬂam-
matory signals of TNFa and p38 might transfer to downstream
molecules, even though p38 MAP kinase activities are inhibited.
Thus, the molecular mechanism of apoptosis in IC/PBS specimens is
likely TNFa and p38 MAPK -mediated [38].
One previous study indicated that phosphorylation of p53 by
p38a could play a role in p53-dependent transcription [39]. In
addition, p53 translocates into the mitochondria to interact with B-
cell lymphoma-2 (Bcl-2) or Bcl-extra large (Bcl-xL), thereby acti-
vating Bax directly or indirectly, leading to caspase-dependent
apoptosis. Therefore, the extranuclear role of p53 in inducing
apoptosis is through mechanisms involving Bad and Bax, which are
the main factors that mediate mitochondrial dysfunction and cell
apoptosis [40]. Our evidence suggested that the apoptotic process
stimulated by p38a was through p53 or regulated by TNFa
concurrently [38].
In various inﬂammatory conditions, the p38 kinases play
important roles in regulating cellular signaling initiated via
a variety of proinﬂammatory cytokines including TNFa, IL-1b, and
IL-6, as well as in modulating the release of such cytokines.
However, both the phosphorylation and activation of p38 MAPK
were enhanced after stimulation with several doses of TNFa
(10e10000 U/mL), indicating that TNFawas the upstream signal of
the p38 MAPK pathway [41]. A previous study indicated that the
activation of p38 MAPK attenuated apoptosis induced by TNFa in
differentiated neuronal PC12 cells [42]. This evidence suggests
multiple roles for TNFa in p38 MAPK activation.
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The vascular system has the critical function of supplying tissues
with nutrients and clearing waste products. Vascular permeability
by any measure is dramatically increased in acute and chronic
inﬂammation, cancer, and wound healing. Angiogenesis also
includes vessel penetration into avascular regions of the tissue and
is crucially dependent on the correct interactions between endo-
thelial cells (which form the vessel lining), pericytes (which
interact externallywith the endothelium) and stromal cells (such as
ﬁbroblasts), and their association with the extracellular matrix and
the vascular basement membrane. Endothelial cells are guided into
a vascular area by macromolecules such as vascular epidermal
growth factor (VEGF), a potent proangiogenic factor and endothe-
lial cell mitogen. This hyperpermeability is mediated by acute or
chronic exposure to vascular permeabilizing agents, particularly
vascular permeability factor/VEGF [43]. These vasoactive and
proinﬂammatory mediators hereby released, such as histamine,
prostaglandins, leukotrienes and tryptase, may possibly play a role
in the pathogenesis of IC/PBS [44].
Glomerulations during hydrodistention are highly associated
with the overexpression of angiogenic growth factors such as
platelet derived endothelial cell growth factor/thymidine phos-
phorylase in the bladder. Thus, it seems likely that neo-
vascularization promoted by angiogenic growth factors has an
important role in the pathogenesis of IC/PBS, inducing glomer-
ulations during hydrodistention [43]. There is increased VEGF and
immature vascularization in patients with IC/PBS, and VEGF
expression is associated with the degree of pain described by
patients. Taken together, VEGF might contribute to pain and
promote the formation of immature vessels in IC/PBS, and the
increased immature vascularization might have a role in glomer-
ulations in patients with IC/PBS [44].
The degree of glomerulations in IC/PBS patients has been noted
to decrease after BoNT-A injection. Although the actual mechanism
for this BoNT-A effect on angiogenesis is not known, it is important
to elucidate which signal molecules are responsible for the regu-
lation of angiogenesis after BoNT-A treatment. In our preliminary
studies we showed that the angiogenesis markers IL-8 and VEGF
were suppressed under BoNT-A therapy (Fig.1). The glomerulations
and increased vascular permeability of IC/PBS may be due to
inﬂammatory stimulation. BoNT-A may block the expression of
angiogenic markers and human umbilical vein endothelial cell
(HUVEC) permeability. According to preliminary results (protein
array and western blotting), our study indicated that the degree of
glomerulations and angiogenic markers could be reduced because
of inﬂammatory suppression after intravesical BoNT-A injection in
some IC/PBS patients. However, not all patients have a decrease in
the degree of glomerulations after BoNT-A injection. Therefore, it is
important to ﬁnd the underlying pathophysiology between
different subgroups of patients to realize the possible mechanism
of successful BoNT-A treatment.
5. Mast cell activity
Mast cell tryptase cleaves protease-activated receptors whose
neotermini then engage G-protein-coupled receptors on mast cells,
sensory nerve endings, the endothelium and neutrophils [45]. This
further activates mast cells and neurons, makes the endothelium
sticky for leukocytes and leaky to ﬂuid, and prompts leukocytes to
release platelet-activating factor (PAF). PAF reinforces the proad-
hesive conversion of the endothelium, which results in leukocyte
emigration from the vasculature [46]. Mast cells are triggered by
numerous stimuli, including infections agents, cytokines, certain
drugs, hormones, and growth factors; when stimulated, theyrelease mediators of inﬂammation that may contribute to the
pathology of IC/PBS [47].
Protease activated receptor (PAR)-2 is activated by a limited
proteolysis at its amino-terminal exodomain by trypsin (but not
thrombin) and tryptase. Trypsin can activate PAR-2 and PAR-4,
while tryptase can only activate PAR-2 [47]. We recently found
that PAR-2 is expressed on ECV304 cells and can be activated by
tryptase. The increased expression of IL-8 induced by tryptase is
inhibited by the speciﬁc monoclonal antibody 11, indicating that
PAR-2 is probably involved in the tryptase-induced inﬂammatory
reaction. Tryptase can activate the MAPK/activator protein-1 (AP-1)
pathway in human peripheral blood eosinophils, causing cytokine
production and release. These results indicate tryptasemay activate
AP-1 through inducing phosphorylation of p38 MAPK in ECV304
cells. MAPKs are upstream activators of AP-1/MAPK signaling
pathways that inﬂuence AP-1 activity by both increasing the
abundance of AP-1 components and by stimulating their activity
directly [45]. It is well known that BoNT-A not only inhibits the
release of acetylcholine and norepinephrine, but also NGF, adeno-
sine triphosphate (ATP), and substance P [21,48].
An increased number of activated mast cells are often seen in
the urothelium, lamina propria and detrusor of IC/PBS patients,
which has led to the theory that mast cells play a major pathogenic
role in some cases of IC/PBS [23]. Mast cells are often increased in
classic ulcerative IC bladders (6 to 10-fold) and approximately
twofold in nonulcer IC bladders compared with controls. Mast cells
are triggered by numerous stimuli, including infectious agents,
cytokines, certain drugs, hormones, and growth factors; when
stimulated, they release mediators of inﬂammation that may
contribute to the pathophysiology of IC/PBS [45]. One study showed
that a high mast cell count, ﬁbrosis, and severe inﬂammation are
associated with poor treatment outcomes for IC/PBS patients.
Biopsies to assess mast cells, ﬁbrosis, and inﬂammation in the
bladder must be performed in a standardized way [49]. The
epithelium and lamina propria should be examined for ulceration,
inﬂammation, granulations, and ﬁbrosis, as well as nonspeciﬁc
inﬂammation, hyperemia, and hemorrhage. Detrusor muscle
abnormalities, the presence of intrafascicular ﬁbrosis, and the mast
cell count should also be reported. Detrusor muscle myopathy is
observed in other bladder diseases but appears to be associated
with more severe IC/PBS. Intrafascicular ﬁbrosis in IC is reproduc-
ible and may be correlated with clinical outcome and stage. The
European Society for the Study of Interstitial Cystitis has developed
a number of recommendations concerning how to perform biopsies
and evaluate the morphologic ﬁndings of biopsies [50].
6. Bladder pain
The nature of neurogenic pain was studied in animal models,
and these pain models indicated that cytokines (TNFa and NGF)
were upregulated in the injured nerves, and neutralizing TNFa
reduced pain behavior [51e53]. Moreover, important research
showed that TNFa and TNF receptor1 mediated the urothelial
apoptotic process in inducible neurogenic cystitis, and TNFa
recombinant protein treatment could induce apoptosis in urothelial
cells [54]. In the past few years, some p38 inhibitors have been used
in the treatment of inﬂammatory diseases in human and animal
models [55,56]. The study of animal models also showed p38
inhibitors strongly interfered with production of TNFa and other
cytokines [56]. However, IC/PBS is considered a heterogeneous
disease, which may have different causes, diagnoses, and symp-
toms. Therapeutic treatments for different types of pathophysi-
ology should not be identical. Our previous study showed that
p38a- and TNFaeinduced apoptosis was present in patients with
nonulcerative/G2e3 IC/PBS [38]. We hypothesize that there are
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7. Clinical experience with BoNT-A injection for IC/PBS
Previous results suggest that BoNT-A has an antinociceptive
effect on bladder afferent pathways in patients with IC/PBS,Fig. 1. The angiogenesis protein array in an IC/PBS patient at baseline and after intravesical B
patient. The fold changes in protein expression between baseline and post-treatment in the
(A) Grade 2 before; and (B) Grade 0 after BoNT-A treatment. Angiogenesis molecules an
(C) protein expression, such as that of VEGF, platelet factor 4, IL-1b, IL-8, CXCL16, and TIMP
CXCL ¼ (C-X-C motif) ligand; GDNF ¼ germ cell nuclear factor; GM-SCF ¼ granulocyte macrop
IL ¼ interleukin; PlGF ¼ placental growth factor; TGF ¼ transforming growth factor; TIMPproducing both symptomatic and functional (i.e., urodynamic)
improvements [48]. In a rat chemical cystitis model, detrusor
injection of BoNT-A increased bladder capacity [57]. Previous
studies indicated that BoNT-A not only inhibited the release of
acetylcholine and norepinephrine, but also NGF, ATP and substance
P [48,58]. We suggested that inhibition of neuroplasticity of the
sensory ﬁbers in the suburothelial space by intravesical BoNT-AoNT-A treatment. The results were compared with baseline measurements in the same
urine samples of the IC/PBS patient were calculated. Glomerulations at baseline were
d vascular inﬂammatory proteins in the array membrane were suppressed by 92%;
-4, was dramatically decreased after BoNT-A injections. BoNT-A ¼ botulinum toxin A;
hage colony-stimulating factor; IC/PBS ¼ interstitial cystitis/painful bladder syndrome;
¼ tissue inhibitor of metalloproteinases; VEGF ¼ vascular endothelial growth factor.
Fig. 2. Cumulative success rates of 83 patients receiving single or repeated BoNT-A
injections. BoNT-A ¼ botulinum toxin A.
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bladder pain and sensory urgency in patients with IC/PBS.
BoNT-A is one of the most powerful neurotoxins inhibiting the
release of neurotransmitters from nerve ﬁbers and the urothelium
[58e61]. BoNT-A is widely reported as effective in the treatment of
neurogenic and idiopathic detrusor overactivity [62,63]; however,
the application of BoNT-A in IC/PBS has been reported in only a few
studies [20,48,64]. BoNT-A reduced bladder pain, impaired bladder
sensation, and chronic inﬂammation in the central nervous system
in animal and human experiments [59,60,64,65]. Although BoNT-A
injections seem promising in treating symptoms of IC/PBS, long-
term follow-up does not show successful outcomes after single
injections [66]. The limited long-term success is possibly due to the
poorly sustained therapeutic effect of a single BoNT-A injection on
chronic bladder inﬂammation.
In our preliminary data, we treated 32 patients who received
four repeated injections and the clinical data showed signiﬁcant
improvement not only in subjective symptoms but also in objective
urodynamic parameters (Table 1). The long-term success rate was
also signiﬁcantly higher in patients who received repeated BoNT-A
injections than in those who received a single injection (Fig. 2). The
results indicate repeated intravesical injections of BoNT-A increase
functional bladder capacity and provide long-term pain relief in
patients with IC/PBS who are refractory to conventional treatment.
The long-term effect of repeated intravesical BoNT-A injections is
better than that of a single injection. These therapeutic effects could
involve not only inhibiting release of acetylcholine in the neuro-
muscular junctions of the detrusor, but also an antiinﬂammatory
response.8. Preliminary laboratory evidence of the antiinﬂammatory
effects of BoNT-A on IC/PBS
Our laboratory performed several pilot studies of the molecular
pathology of BoNT-A effects on IC/PBS urothelial dysfunction,
characterized by decreases in inﬂammation, apoptosis, and angio-
genesis after BoNT-A injections. These molecular ﬁndings are
compatible with the clinical characteristics of IC/PBS patients after
repeated BoNT-A injections.
There was a reduction of activated mast cells in IC/PBS bladders
after BoNT-A injection. However, apoptotic urothelial cells did not
vanish completely after a single BoNT-A injection, suggesting
repeated BoNT-A injections are necessary to achieve completeTable 1
Changes of parameters in 32 patients receiving four repeated BoNT-A injections.
BoNT-A  4 BoNT-A-1 BoNT-A-2 BoNT-A-3 BoNT-A-4 p value
(N ¼ 32) Baseline Baseline Baseline Baseline
ICSI 12.9  3.47 9.27  4.55 8.9  3.66 8.57  3.94 0.000
ICPI 11.8  3.0 8.8  4.47 8.2  4.13 6.63  4.6 0.000
OSS (ICSI þ ICPI) 24.8  6.18 18.1  8.68 17.1  7.57 15.2  8.38 0.000
VAS 5.8  2.27 4.03  2.34 3.70  2.35 3.03  2.3 0.000
FBC 139  81.2 170  87.6 210  100 228  118 0.000
Frequency 13.8  5.1 11.3  6.31 11.5  5.93 10.3  4.94 0.029
Nocturia 3.73  2.12 3.13  1.85 3.13  2.33 3.4  2.79 0.384
Qmax 14.4  4.95 13.5  7.13 13.6  4.99 12.4  6.22 0.535
Volume 2527  111 279  144 296  137 283  150 0.289
PVR 9.84  21.92 41.2  67.4 38.8  82.3 47.3  66.7 0.127
CBC 262  116 323  126 338  113 335  145 0.009
MBC 711  217 752  218 756  202 739  186 0.472
GRA 0.30  0.92 1.40  1.19 1.53  0.78 1.77  1.25 0.000
BoNT-A ¼ botulinum toxin A; CBC ¼ cystometric bladder capacity; FBC ¼ functional
bladder capacity; GRA ¼ global response assessment; ICPI ¼ interstitial cystitis
problem index; ICSI ¼ interstitial cystitis symptom index; MBC ¼ maximal bladder
capacity; OSS ¼ O’Leary-Sant symptom score; PVR ¼ postvoid residual;
Qmax ¼ maximum ﬂow rate; VAS ¼ visual analog score.resolution. To investigate the effect of BoNT-A and prove the
pathologic mechanism of IC/PBS we need to prove that (a) uro-
thelial cell apoptosis, (b) mast cell activity, and (c) angiogenesis and
the degree of glomerulation all decrease after repeated BoNT-A
injections. Patients with good responses to repeated BoNT-A
injections should have a higher degree of improvement and those
who receive repeated BoNT-A injections should show a higher
degree of improvement than those receiving a single injection.
Our study indicated that inﬂammatory effects could be reduced
with intravesical BoNT-A injection and urothelial apoptosis is also
inhibited in IC/PBS. These results could provide evidence for the
existing pathophysiology of IC/PBS, as well as the actual mechanism
of action of BoNT-A in treating IC/PBS. Previous research has indi-
cated that tryptase induced phosphorylation of p38 MAPK, causing
cytokine production and release [67]. According to this result, we
suggested that phosphorylation of p38 might be induced by tryp-
tase in IC/PBS. We will investigate whether the decrease of mast
cells leads to p-p38 downregulation after BoNT-A injection.
To investigate the molecular changes of angiogenesis and
inﬂammation at baseline and after BoNT-A treatment and provide
evidence for the actual mechanism of action of BoNT-A treatment
for IC/PBS, it must be proved that VEGF expression and mast cell
activity in IC/PBS are decreased after repeated BoNT-A injections.
Mast cell tryptase may exert its angiogenic effects in part through
selective stimulation of angiogenic chemokines [68]. In ourTable 2
Changes of parameters in patients receiving repeated BoNT-A injection.
Baseline Repeated BoNT-A
injections
P value
VAS 5.80  2.27 3.03  2.30 0.000
MBC 711.7  217.2 738.7  186.3 0.46
Glomerulation 1.80  1.06 1.20  1.06 0.026
GRA 0.30  0.92 1.20  1.06 0.000
Tryptase 100 64.2  17.4 0.001
Bax 100 84.3  21.9 0.050
P-p38 100 66.3  15.9 0.000
SNAP25 100 53.1  11.7 0.001
GRA ¼ global response assessment; MBC ¼maximal bladder capacity; VAS ¼ visual
analog score.
Fig. 3. Apoptotic cells and mast cells are decreased in the bladder after repeated BoNT-A injections. BoNT-A ¼ botulinum toxin A.
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expression of Intracellular adhesions molecules, which accompany
increases in vascular permeability. In addition, the phosphorylation
of p38 can be upregulated by TNFa, but not tryptase in HUVEC.
We performed a pilot study investigating 28 patients with IC/
PBS who received repeated BoNT-A injections. Our pilot study
demonstrated that the degree of glomerulations, inﬂammatory
markers (tryptase) and apoptotic markers (Bax and p38) could be
reduced because of inﬂammatory suppression after repeated
intravesical BoNT-A injections in some IC/PBS patients. The bladderFig. 4. Changes in the proapoptotic proteins Bax and phosphorylated p38 in patients
from baseline to 6 months after BoNT-A injection. BL ¼ baseline; BoNT-A ¼ botulinum
toxin A; Btx ¼ 6 months after BoNT-A injection.tissues also showed the intensity of synaptosome- associated
protein of 25 kd was signiﬁcantly decreased after three repeated
BoNT-A injections, suggesting a BoNT-A effect on the bladder
specimens. These results could provide evidence for the existing
pathophysiology of IC/PBS as well as the actual mechanism of
action of BoNT-A in treating IC/PBS (Table 2).
In a histologic analysis, the results of apoptotic cell andmast cell
activity stains indicated that inﬂammation was decreased in
bladder tissue after repeated BoNT-A injections (Fig. 3). Although
statistical analysis showed no signiﬁcant decrease in urothelial cell
apoptosis overall in patients after BoNT-A injections, western
blotting showed signiﬁcant reductions in tryptase, Bax and phos-
pho-p38a in these bladders specimens after repeated BoNT-A
injections. (Fig. 4; Table 2). Based on these results, our pilot study
indicated that the inﬂammatory effect in IC/PBS bladders could be
reduced after repeated intravesical BoNT-A injections but urothelial
apoptosis was not inhibited completely after a single BoNT-A
injection in some IC/PBS patients. These results could provide
evidence for the existing pathophysiology of IC/PBS, as well as the
actual mechanism of action of BoNT-A in treating IC/PBS.References
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